COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #214 of 255
12/14 Late treatment study
Naseem et al., medRxiv, doi:10.1101/2020.12.13.20247254 (Preprint)
Predicting mortality in SARS-COV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep Neural Network
Source   PDF   Share   Tweet
Retrospective 1,214 hospitalized patients in Pakistan, 77 HCQ patients, showing 33% lower mortality with HCQ, multivariate Cox HR 0.67, p = 0.34.

Naseem et al., 12/14/2020, retrospective, Pakistan, South Asia, preprint, 5 authors.
risk of death, 33.3% lower, RR 0.67, p = 0.34, treatment 77, control 1137, multivariate Cox.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 255 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit